pegfilgrastim pegfilgrastim pegfilgrastim, sold under the brand name neulasta among others, is a pegylated form of the recombinant human granulocyte colony-stimulating factor (gcsf) analog filgrastim. it serves to stimulate the production of white blood cells (neutrophils). pegfilgrastim was developed by amgen. pegfilgrastimclinical datatrade namesneulastabiosimilarspegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-fpgk, pegfilgrastim-jmdb, pegfilgrastim-pbbk, cegfila, filpegla, fulphila, fylnetra, grasustek, lapelga, neutropeg, nyvepria, pelgraz, pelmeg, ristempa, stimufend, tezmota, udenyca, ziextenzoahfs/drugs.commonographmedlineplusa607058license data eu ema: by inn us dailymed: pegfilgrastim pregnancycategory au: b3 routes ofadministrationsubcutaneousatc codel03aa13 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only / schedule d uk: pom (prescription only) us: ℞-only eu: rx-only in general: ℞ (prescription only) pharmacokinetic dataelimination half-life15–80 hrsidentifiers iupac name n-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with .alpha.-methyl-.omega.-hydroxypoly(oxyethylene) cas number208265-92-3 yiuphar/bps6969drugbankdb00019 ychemspidernoneunii3a58010674keggd06889 ychemblchembl1201568 necha infocard100.169.155 chemical and physical dataformulac845h1343n223o243s9molar mass18802.90 g·mol−1 ny (what is this?) (verify) pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy. pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). pegfilgrastim was approved for medical use in the united states in january 2002, in the european union in august 2002, and in australia in september 2002. medical uses pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome). biosimilars